Navigation Links
mood in Biological Technology

Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease

... cognitive deficits and mood disorders ROCKLAND, Mass., Oct. 14 /PRNewswire/ ... projects under MJFF's Cognitive Deficits and mood Disorders in Parkinson's Disease initiative. ... The development of treatments for cognitive and mood symptoms of PD has been hindered by a lack of ...

Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder

... The study compared the time to the next mood episode, also known as a relapse, in FRBD ... most patients, standard treatment consisted of mood stabilizers, antidepressants, anxiolytics or ... relapse was defined as the first occurrence of a mood episode as determined by an independent Relapse ...

Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo

... and Norepinephrine Reuptake Inhibitor, Improves mood and Menopausal Symptoms in Women With Hot Flushes ... 100 mg or 150 mg improved total mood disturbance score as measured by the Profile of mood States (POMS), and climacteric symptoms ...

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

... advantage to millions of Americans who struggle with obesity." The mood and weight-related quality of life findings observed in the Contrave group ... Contrave was not associated with suicidality or worsening of mood or depressive symptoms, and in fact was associated with a decreased ...

Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... is common in patients with depression, bipolar disorder and other mood disorders, Alzheimer's disease (AD) and neurological disorders. For ... and in other sleep disorders such as sleep disorders in depression, other mood disorders, Alzheimer's disease and schizophrenia. ABOUT ...

FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder

... CONSTA(R) for adjunctive maintenance treatment to delay the occurrence of mood episodes in patients with bipolar disorder who relapsed frequently. ... energy and ability to function. It is often characterized by debilitating mood swings from extreme highs (mania) to extreme lows (depression), and ...

Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease

... in the brain. The disease is characterized by uncontrollable movements and mood swings or depression, followed by dementia. Preclinical findings on ... drugs can only minimize symptoms, such as uncontrollable movements and mood swings. The FDA's decision to grant cysteamine orphan drug designation ...

January Market Jitters Fails to Derail Biotech

... a recession but is also rapidly weakening had investors in a skittish mood during January. However, biotech held steady with the Burrill Biotech ... the event were reporting updated clinical and year end ... and the mood was quite optimistic. Most notable was Pharmasset, whose shares surged ...

Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders

... to final dosing and less than a year after the rights to rufinamide in mood disorders were obtained from Novartis in an exclusive licensing ... models and further justify investigation of the effect of rufinamide for mood disorders," said Stephen Bandak, Synosia's Chief Medical Officer. "The ...

Atherotech Taps Canyons Medical Center Director, Lipidologist as Chief Medical Officer

... and continue to practice a full range of medicine, including diabetes care, cardiovascular disease, hypertension, dyslipidemia, and bipolar and mood disorders. "I'm excited to join Atherotech with their dedication to lipid assessment and risk management," said Cobble. "Too many ...

Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies

... Patients taking Vimpat should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. The most common adverse reactions occurring in greater than or equal to 10 percent of Vimpat-treated patients, and greater than ...

Genomas and Institute of Living Among Organizers of Pharmacogenetics Symposium at 2009 Annual Meeting of the American Psychiatric Association

... Hospital, Hartford, CT Cytochrome P-450 2D6, 2C19, and Serotonin Transporter Genotyping for Depressed Inpatients at the Mayo Clinic mood Disorders Unit Simon Kung, M.D. Mayo Clinic, Rochester, MN Pharmacogenetic Testing in Psychiatry: Early Adopters' Attitudes and Practices ...

Neurocrine Biosciences Reports First Quarter 2009 Results

... and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders. GSK has advanced a novel lead CRF1 receptor antagonist compound, 561679, into a Phase II trial. This six week randomized, ...

First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease

... as osteoporosis, resulting in increased risk for hip or spinal fractures, and metabolic disturbances including obesity, heart disease, and diabetes. mood disturbances are also associated with chronic corticosteroid use. "The tapering of systemic corticosteroids to 5 mg or less per day, as ...

Vanda Pharmaceuticals Reports First Quarter 2009 Results

... the FDA, Vanda is concentrating its efforts on the design and evaluation of clinical development options for tasimelteon, its compound for sleep and mood disorders, including Circadian Rhythm Sleep Disorders. FINANCIAL DETAILS * Operating Expenses. First quarter 2009 R&D ...

Psylin Neurosciences Commences Development of Compound for Depression

... first compound in Psylin's pipeline to enter into clinical development. Other compounds are being investigated for development as antipsychotic and mood stabilizing therapies. Amylin's proprietary peptide library known as PHORMOL encompasses an extensive panel of potentially valuable biologics ...

CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors

... targeting the CB1 receptor, such as agents being developed to treat obesity, have been associated with such central side effects as negative mood and depression. Furthermore, cannabinoid agonists targeting CB1 receptors, including candidates being developed for pain relief, have demonstrated ...

Metametrix Introduces the New TRIAD(SM) Bloodspot Profile

... SM Comprehensive Profile: Measures organic acid levels to reveal the nutritional and metabolic basis of patient symptoms, including anxiety, mood changes, and immune responses. Bloodspot Amino Acids Plasma 20 Profile: Determines essential amino acid imbalances that affect both ...

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results

... the FDA, Vanda is concentrating its efforts on the design and evaluation of clinical development options for tasimelteon, its compound for sleep and mood disorders. Results of prior phase II and III clinical trials for tasimelteon were published in the December 2008 issue of The Lancet. On ...

Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy

... taking Vimpat(R) should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. The most common adverse reactions occurring in >10 percent of Vimpat(R)-treated patients, and greater than placebo, were ...

Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting

... taking Vimpat(R) should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. The most common adverse reactions occurring in >10 percent of Vimpat(R)-treated patients, and greater than placebo, were ...

Neurocrine Biosciences Reports Third Quarter 2008 Results

... and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and irritable bowel syndrome (IBS). There are currently three distinct CRF compounds in clinical development that have arisen out of the ...

Global Psychiatrists Unite to Improve Services in Mental Health

... Universitat Munchen, Munich, Germany Dr Mario Maj, The Department of Psychiatry, University of Naples, Italy Dr Roger McIntyre, mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada Dr Dieter Naber, the Department for Psychiatry and ...

Neurocrine Biosciences Reports Second Quarter 2008 Results

... and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and irritable bowel syndrome (IBS). There are currently three distinct CRF compounds in clinical development that have arisen out of the ...

FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults

... the condition is often chronic, with prominent symptoms and impairment spanning into adulthood, and is often associated with co-occurring anxiety, mood and disruptive disorders as well as substance abuse(3). According to the NIMH, ADHD is thought to be a biological condition, usually inherited, and ...

Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference

... compound for the treatment of schizophrenia. Vanda's second product candidate, tasimelteon (VEC-162), is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for chronic primary insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of ...

Synosia Starts Phase II Efficacy Trial For Rufinamide

... 2007 in an exclusive worldwide licensing agreement, outside of Japan, to develop and commercialize rufinamide for the treatment of anxiety and other mood disorders. Rufinamide is also marketed by Eisai in Europe as a drug to treat a form of epilepsy under the tradename Inovelon(R). "Given the ...

BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing

... of experience in the biotechnology and pharmaceutical industries." "BCI's application of groundbreaking science in neurogenesis to the treatment of mood disorders and other neurological conditions has the potential to provide a novel treatment paradigm," commented William Bertrand, Jr. senior vice ...

FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder

... five or more of the following symptoms that have been present for at least two weeks, and at least one of the symptoms must be either depressed mood or loss of interest or pleasure: depressed mood; loss of interest or pleasure; changes in appetite or weight; changes in sleeping patterns; ...

Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP

... 14 percent of those patients who received a placebo. Additionally, studies showed that the drug also doubled cases of anxiety, depression, and other mood disorders when compared to placebo. Analysts had predicted that Zimulti would have been a multibillion-dollar product worldwide, assuming that it was ...

Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome

... a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body, accompanied by severe fatigue, insomnia and mood symptoms. According to the American College of Rheumatology, FMS is estimated to affect over six million people in the United States. FMS is most ...

Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer

... by 3 patients and included reversible fatigue and headache, increased liver function tests that resolved in 9 days and unsteady gait and euphoric mood that resolved in a single day. Noticeably absent were toxicities associated with conventional chemotherapy, including alopecia, myelosuppression, ...

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)

... who cannot find sufficient relief for their symptoms with antidepressants alone," said Madhukar Trivedi, M.D., Professor and Chief- Division of mood Disorders, University of Texas Southwestern Medical School, Dallas, Texas. "Now physicians have a proven new option they can add to their patients' ...

National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment

... of less than two percent. ENDOMETRIN is expected to have adverse reactions to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness). About Ferring Pharmaceuticals Ferring Pharmaceuticals, part of the Ferring Group, a privately ...

Biotech Continues Upward Climb in October

... issues. We certainly see that our prediction of 30 biotech IPOs completed in 2007 will come to ... it could even be more given the prevailing mood of the markets toward biotech." Biotech Industry's Market Cap The biotech industry's market cap rose 3.6% in October to close at $499 billion. ...

Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results

... serotonin levels could be reduced in the intestine without affecting levels of the neurotransmitter in the brain, where it mediates mood and other behaviors. -- Lexicon received stockholder approval for and completed a financing transaction with Invus, L.P., under which Invus ...

Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder

... safety of asenapine," said Roger S. McIntyre, M.D., Associate Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. "The complex nature of bipolar disorders suggests that we should ...

Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market

... a scientifically validated and effective treatment for sleep and circadian rhythm related disorders such as jet lag, chronic insufficient sleep and mood disorders. Light therapy treatment is currently available on a non-prescription basis and may be used across the broad spectrum of people suffering ...

Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome

... that serotonin levels could be predictably reduced in the intestine without affecting levels of the neurotransmitter in the brain, where it mediates mood and other behaviors. The data were presented here today at the American Chemical Society National Meeting and Exposition in Boston. "Our genetic ...
Other Contents
(Date:10/19/2014)... over the last 30 years contributed only marginally ... that time, according to a new study published ... "Energy access is fundamental to development: it brings ... communication, and health," says IIASA researcher Shonali Pachauri, ... access is widely agreed to be an important ...
(Date:10/17/2014)... in German . ... day in order to reproduce? And why are there two ... the latest issue of the research journal Molecular Human ... Steven Ramm from Bielefeld University Bielefeld has compiled this special ... for a female to copulate with several males in quick ...
(Date:10/16/2014)... new synthesis of recent research findings to inform their ... two states. , The Ecology and Management of ... Synthesis of the Relevant Biophysical Science and Implications for ... the U.S. Forest Service,s Pacific Northwest Research Station, is ... a synthesis of the large body of scientific information ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2
(Date:10/22/2014)... only 24 hours in a day, that doesn’t seem to be ... their busy schedules for exercise and fitness. Fortunately, one does not ... shape. Here are five ways you can reach your fitness and ... Commute , Consider riding a bike or taking the bus or ... If you must use your car to get to work, start ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
(Date:10/20/2014)... 20, 2014 The newly updated Worldwide ... of thousands of facts, figures and forecasts on the ... medical sector forecast categories the Worldwide Medical Market ... and national views on the worldwide medical market to ... report gives you data for 2010-2019, covering each country ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
Other TagsOther Tags